CDK4/6抑制剂联合放疗在转移性乳腺癌患者中的安全性
回顾性分析两家欧洲学术机构132例转移性HR+/HER2-乳腺癌患者,其中57例(43.2%)接受放疗。同步放疗与≥3级不良事件无显著相关(p=0.19),与CDK4/6i减量(p=0.49)和停药(p=0.14)亦无关联,且未影响无进展生存(p=0.71)和总生存(p=0.55)。
要点
- 同步放疗未显著增加≥3级不良事件(p=0.19)或任何级别不良事件(p=1.0)。
- 同步放疗与CDK4/6i减量率(p=0.49)和停药率(p=0.14)无显著关联。
- 同步放疗未影响无进展生存(p=0.71)和总生存(p=0.55)。
核心结论
- 研究数据显示同步放疗未增加严重毒性,且未影响全身治疗的实施,结果令人鼓舞。
研究设计与样本
- 回顾性收集2017年9月至2020年2月两家欧洲学术机构连续接受CDK4/6i治疗的转移性HR+/HER2-乳腺癌患者资料,共分析132例女性。
主要发现
- 57例(43.2%)患者接受放疗,共照射70个病灶;全组中位年龄52.1岁(范围32.3-78.2)。
- 同步放疗与≥3级不良事件无显著相关(p=0.19),与任何级别不良事件亦无显著相关(p=1.0)。
- 同步放疗与CDK4/6i减量率(p=0.49)和停药率(p=0.14)无显著关联。
- 中位随访18.8个月,全组无进展生存率为35%,总生存率为38.7%;同步放疗未影响无进展生存(p=0.71)和总生存(p=0.55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) currently represent the standard of care for the initial treatment of patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The aim of our study is to evaluate the safety of the use of concomitant radiation therapy (RT) in a consecutive series of HR+/HER2- patients treated in two academic institutions with CDK4/6i in the metastatic setting. METHODS AND MATERIALS: From September 2017 to February 2020, we retrospectively collected and analysed data on a sequential series of patients treated with CDK4/6i, receiving RT or not, at two European institutions. Primary outcome of the study was the association between RT and any adverse events (AEs) ≥ G3. Secondary outcomes were the association between RT and any AEs (any grade), CDK4/6i dose reduction rate, and CDK4/6i treatment discontinuation rate. RESULTS: We analysed a total of 132 consecutive women; RT was prescribed in 57 (43.2%) patients (70 irradiated lesions). The median age of the series was 52.1 years (range 32.3-78.2). Concomitant RT administration was not significantly related to higher AEs ≥ G3 (p = 0.19) and any grade AEs (p = 1.0); there was no association with RT and CDK4/6i dose reduction (p = 0.49) and discontinuation rates (p = 0.14). At a median follow-up of 18.8 months, the progression-free survival (PFS) rate was 35% and the overall survival (OS) rate was 38.7% in the whole group. The use of concomitant RT did not affect both PFS (p = 0.71) and OS rates (p = 0.55). CONCLUSIONS: Our data are encouraging regarding the safety of this combination, showing that concurrent RT did not increase severe toxicity and did not have an impact on systemic treatment conduction.
引用
- Visani L, Livi L, Ratosa I, et al. Safety of CDK4/6 inhibitors and concomitant radiation therapy in patients affected by metastatic breast cancer. Radiother Oncol. 2022. PMID: 36349599. doi:10.1016/j.radonc.2022.10.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。